AU2021343770A1 - Amine derivative - Google Patents

Amine derivative Download PDF

Info

Publication number
AU2021343770A1
AU2021343770A1 AU2021343770A AU2021343770A AU2021343770A1 AU 2021343770 A1 AU2021343770 A1 AU 2021343770A1 AU 2021343770 A AU2021343770 A AU 2021343770A AU 2021343770 A AU2021343770 A AU 2021343770A AU 2021343770 A1 AU2021343770 A1 AU 2021343770A1
Authority
AU
Australia
Prior art keywords
benzothiazol
dihydrofuro
optionally substituted
imidazol
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021343770A
Other languages
English (en)
Other versions
AU2021343770A9 (en
Inventor
Yuko Asamitsu
Wataru Kawahata
Hideki Moriyama
Shingo Tojo
Daisuke Urabe
Hitoshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carna Biosciences Inc
Original Assignee
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc
Publication of AU2021343770A1 publication Critical patent/AU2021343770A1/en
Assigned to CARNA BIOSCIENCES, INC. reassignment CARNA BIOSCIENCES, INC. Request for Assignment Assignors: CARNA BIOSCIENCES, INC., Sumitomo Pharma Co., Ltd.
Publication of AU2021343770A9 publication Critical patent/AU2021343770A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021343770A 2020-09-18 2021-09-17 Amine derivative Pending AU2021343770A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020-157398 2020-09-18
JP2020157398 2020-09-18
JP2021122893 2021-07-28
JP2021-122893 2021-07-28
PCT/JP2021/034327 WO2022059779A1 (ja) 2020-09-18 2021-09-17 アミン誘導体

Publications (2)

Publication Number Publication Date
AU2021343770A1 true AU2021343770A1 (en) 2023-05-18
AU2021343770A9 AU2021343770A9 (en) 2024-09-12

Family

ID=80776131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021343770A Pending AU2021343770A1 (en) 2020-09-18 2021-09-17 Amine derivative

Country Status (10)

Country Link
US (1) US20230365589A1 (https=)
EP (1) EP4215534A4 (https=)
JP (2) JP7706775B2 (https=)
KR (1) KR20230069162A (https=)
CN (1) CN116209441A (https=)
AU (1) AU2021343770A1 (https=)
BR (1) BR112023003807A2 (https=)
CA (1) CA3191617A1 (https=)
MX (1) MX2023003245A (https=)
WO (1) WO2022059779A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008470A1 (ja) * 2021-07-28 2023-02-02 住友ファーマ株式会社 縮環アミン誘導体
WO2025170029A1 (ja) * 2024-02-09 2025-08-14 カルナバイオサイエンス株式会社 ジヒドロキナゾリノン誘導体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084116A (ko) * 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
JP2010163361A (ja) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
KR20100010894A (ko) 2008-07-23 2010-02-02 가부시키가이샤 키노파마 Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
US9446044B2 (en) 2011-08-19 2016-09-20 Diaxonhit DYRK1 inhibitors and uses thereof
WO2013043002A1 (en) 2011-09-23 2013-03-28 Yuhan Corporation Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
JP2017516850A (ja) 2014-05-23 2017-06-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN109206537B (zh) 2018-10-10 2021-04-09 华熙生物科技股份有限公司 一种乙酰化透明质酸钠的制备方法及其应用
US20230138851A1 (en) * 2020-01-30 2023-05-04 Carna Biosciences, Inc. Novel alkyne derivatives

Also Published As

Publication number Publication date
AU2021343770A9 (en) 2024-09-12
KR20230069162A (ko) 2023-05-18
MX2023003245A (es) 2023-04-11
JP2025134941A (ja) 2025-09-17
JP7706775B2 (ja) 2025-07-14
EP4215534A1 (en) 2023-07-26
US20230365589A1 (en) 2023-11-16
EP4215534A4 (en) 2024-10-02
BR112023003807A2 (pt) 2023-03-28
CA3191617A1 (en) 2022-03-24
CN116209441A (zh) 2023-06-02
JPWO2022059779A1 (https=) 2022-03-24
TW202227459A (zh) 2022-07-16
WO2022059779A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
US12077536B2 (en) BCL-2 inhibitors
CA3107411C (en) Heterobicyclic compounds for inhibiting the activity of shp2
AU2021256235B2 (en) Imidazolidinone derivatives and medical use thereof
CA2767899C (en) Nitrogen-containing spiro-ring compound and medicinal use of same
CA3163007A1 (en) Inhibitors of mutant forms of egfr
AU2017225371A1 (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
AU2013290054A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
CA2672565A1 (en) Imidazothiazole derivatives
EP3844159B1 (en) Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
EP2708540B1 (en) Pyrimido-diazepinone compound
AU2019326633B2 (en) High activity sting protein agonist
WO2014003098A1 (ja) 三環性化合物
WO2020048605A1 (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease
JP2025134941A (ja) アミン誘導体
EP3571198A1 (en) Bicyclic amines as novel jak kinase inhibitors
EP4559917A1 (en) Compound for recovering p53 mutation function and use thereof
CA3159093A1 (en) Compounds as cd73 inhibitors
AU2022240650B2 (en) Estrogen receptor antagonist
TWI915421B (zh) 胺衍生物
HK40090757A (en) Amine derivative
JP2023138470A (ja) アミン誘導体を含有する医薬
EP4516793A1 (en) Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof
US20250084098A1 (en) Fused-ring amine derivative

Legal Events

Date Code Title Description
SREP Specification republished